Feature|Articles|April 17, 2024
- Pharmaceutical Executive: April 2024
- Volume 44
- Issue 4
Pharmaceutical Executive: April 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
Power in Partneringover 1 year ago
The IRA Impact: Navigating Its Evolving Complexitiesover 1 year ago
Fighting for Innovationover 1 year ago
Say Hello to Flexible: Reimagining the Patient Journeyover 1 year ago
Aspiring for the C-Suite? Consider Being a Chief of Staffover 1 year ago
Latent Benefit of Access Restrictions for Rare Conditionsover 1 year ago
The Pharmaceutical Playbook for Asia’s Private Marketover 1 year ago
Operating Models for Successful DOL EngagementNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
2
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
3
Alnylam Announces $250 Million Investment in Massachusetts Facility
4
President Trump Announces Nine More TrumpRx Participants
5

